Addex Therapeutics reported third-quarter 2025 results and a focused R&D update, highlighting continued progress of its GABAB positive allosteric modulator program in chronic cough and preparation of dipraglurant, an mGlu5 negative allosteric modulator, for clinical studies in post-stroke recovery. Financially, the company posted a CHF 1.6 million net loss for the quarter and a CHF 0.7 million operating loss, with cash and cash equivalents at CHF 2.2 million. Income declined versus 2024 as the R&D phase of its Indivior collaboration concluded, while a CHF 0.9 million share of losses from its 20% stake in Neurosterix weighed on the period. Year to date, the net loss from continuing operations reached CHF 5.0 million.
The strategic question is whether Addex can translate mechanistic promise into a financed clinical path before its runway forces hard choices. With CHF 2.2 million on hand and a lean operating profile, the company is operating in a capital market that rewards crisp thesis, fast proof-of-concept, and credible partnering. For senior commercial and medical leaders, the near-term signal will be how Addex sequences IND-enabling and early clinical steps for the cough asset and whether it secures non-dilutive capital or a co-development structure that de-risks advancement.
Chronic refractory cough is primed for competitive stratification. P2X3 antagonists have set the pace, but tolerability—especially taste disturbance—remains a commercial friction point. A GABAB PAM could differentiate by leveraging central antitussive pathways with a potentially cleaner side-effect profile than direct agonists like baclofen. To matter for payers and prescribers, the program will need robust objective cough frequency reductions and validated patient-reported outcomes that translate to quality-of-life gains. Medical Affairs teams should anticipate heavy education demands across pulmonology and ENT, clear guidance on patient selection (including P2X3 non-responders or intolerant patients), and early real-world data on adherence and daytime functioning. If the mechanism delivers clinically meaningful benefit with fewer discontinuations, the asset could secure a second-line foothold and challenge incumbents in defined subpopulations.
Dipraglurant’s repositioning into post-stroke recovery aims at a large unmet need where few pharmacologic options complement rehabilitation. The hurdle is trial design: timing post-event, functional endpoints that resonate with stroke networks, and payer-relevant outcomes such as return-to-independence and reduced caregiver burden. Success will hinge on cross-functional execution, including hospital-based site activation, alignment with rehabilitation pathways, and early health economics modeling. If signals align, the indication could attract strategic partners given the scale of the stroke burden and the scarcity of competitors with mechanistically targeted neurorecovery agents.
Addex’s external portfolio adds optionality but also near-term P&L drag. Indivior’s selection of a GABAB PAM for substance use disorders and completion of IND-enabling work positions that program for potential clinical entry, with milestone visibility a meaningful catalyst if timelines hold. The Neurosterix spinout diversifies exposure to M4 PAM and mGlu7 NAM in psychiatry, reflecting an industry-wide pivot to capital-light structures and modular CNS innovation, though equity-accounted losses highlight the cost of maintaining that optionality pre-revenue.
With cough and post-stroke programs approaching decision points, the next six to twelve months will hinge on financing and partnerships. The industry question is whether an allosteric-first neurology platform can carve defensible niches as larger players consolidate chronic cough and neuropsychiatry. The signal to watch: can Addex secure the capital and clinical readouts that convert mechanistic elegance into payer-accepted, guideline-relevant value before the market window narrows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
